71 related articles for article (PubMed ID: 7645953)
21. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
22. [Electron microscopic observation on the killing of human lung carcinoma cells by lymphokine-activated killer cells (LAK cells) in vitro].
Shi J
Zhonghua Yi Xue Za Zhi; 1990 Jun; 70(6):319-21, 22. PubMed ID: 2169980
[TBL] [Abstract][Full Text] [Related]
23. [Lymphokine-activated killer cell induced from cord blood].
Wang YF; Jiang S
Zhonghua Fu Chan Ke Za Zhi; 1994 Feb; 29(2):78-81, 122-3. PubMed ID: 8033630
[TBL] [Abstract][Full Text] [Related]
24. Lymphokine-activated killer (LAK) cell anti-HIV-1 ADCC reactivity: a potential strategy for reduction of virus-infected cellular reservoirs.
Tyler DS; Stanley SD; Bartlett JA; Bolognesi DP; Weinhold KJ
J Surg Res; 1998 Oct; 79(2):115-20. PubMed ID: 9758725
[TBL] [Abstract][Full Text] [Related]
25. [The effect of MPS on LAK cell growth and its cytotoxic activity against laryngeal cancer (HEP-2)].
Wang J; Zhu X; Chen J
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1996; 31(5):283-6. PubMed ID: 9642362
[TBL] [Abstract][Full Text] [Related]
26. The glycosylation profile of interleukin-2 activated human lymphocytes correlates to their anti-tumor activity.
Voshol H; Dullens HF; Den Otter W; Vliegenthart JF
Anticancer Res; 1996; 16(1):155-9. PubMed ID: 8615602
[TBL] [Abstract][Full Text] [Related]
27. Effect of TNF-alpha and IFN-alpha on the proliferation and cytotoxicity of lymphokine-activated killer cells in patients with bladder cancer.
Wang Z; Cheng Y; Zheng R; Qin D; Liu G
Chin Med J (Engl); 1997 Mar; 110(3):180-3. PubMed ID: 9594335
[TBL] [Abstract][Full Text] [Related]
28. Sequential TNF and TGF-beta regulation of expansion and induction of cytotoxicity in long-term cultures of lymphokine-activated killer cells.
Koberda J; Przepiorka D; Moser RP; Grimm EE
Lymphokine Cytokine Res; 1994 Apr; 13(2):139-45. PubMed ID: 8061115
[TBL] [Abstract][Full Text] [Related]
29. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells.
Komatsu F; Kajiwara M
Oncol Res; 1998; 10(10):483-9. PubMed ID: 10338151
[TBL] [Abstract][Full Text] [Related]
30. Characterization of the M(r) 65,000 lymphokine-activated killer proteins phosphorylated after tumor target binding: evidence that pp65a and pp65b are phosphorylated forms of L-plastin.
Frederick MJ; Rodriguez LV; Johnston DA; Darnay BG; Grimm EA
Cancer Res; 1996 Jan; 56(1):138-44. PubMed ID: 8548753
[TBL] [Abstract][Full Text] [Related]
31. Cooperation between CD44 and LFA-1/CD11a adhesion receptors in lymphokine-activated killer cell cytotoxicity.
Matsumoto G; Nghiem MP; Nozaki N; Schmits R; Penninger JM
J Immunol; 1998 Jun; 160(12):5781-9. PubMed ID: 9637488
[TBL] [Abstract][Full Text] [Related]
32. T cells and monocytes regulate the generation and functional activity of natural killer-derived lymphokine-activated killer cells.
Atzpodien J; Gulati SC
Stem Cells; 1993 Nov; 11(6):511-8. PubMed ID: 8111310
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-2 killer cells: in vitro evaluation of combination with prothymosin alpha.
López-Rodríguez JL; Cordero OJ; Sarandeses C; Viñuela J; Nogueira M
Lymphokine Cytokine Res; 1994 Jun; 13(3):175-82. PubMed ID: 7948426
[TBL] [Abstract][Full Text] [Related]
34. A lymphokine-activated killer (LAK)-resistant cell line, and low expression of adhesion molecules LFA-3 and VCAM-1 on its cell surface.
Komatsu F; Kajiwara M
Oncol Res; 1998; 10(5):263-9. PubMed ID: 9802061
[TBL] [Abstract][Full Text] [Related]
35. Tretinoin or retinol enhancement of lymphokine-activated killer cell proliferation and cytotoxicity against human bladder cancer cells in vitro.
Wang ZP; Zheng RL; Chen YR; Liu GD
Zhongguo Yao Li Xue Bao; 1997 Nov; 18(6):522-4. PubMed ID: 10322910
[TBL] [Abstract][Full Text] [Related]
36. Role of function-associated molecules in target cell lysis: analysis of rat adherent lymphokine-activated killer cells.
Jaso-Friedmann L; Leary JH; Evans DL
Nat Immun; 1993; 12(6):316-25. PubMed ID: 8268715
[TBL] [Abstract][Full Text] [Related]
37. Anti-tumoral capabilities of effector cells after IFN-alpha or CpG-motif treatment of cocultured dendritic cells.
Erhardt M; Schmidt-Wolf IG; Sievers E; Frank S; Strehl J; von Lilienfeld-Toal M; Gorschlüter M
Arch Immunol Ther Exp (Warsz); 2006; 54(6):403-9. PubMed ID: 17122879
[TBL] [Abstract][Full Text] [Related]
38. Interactions of lymphokine-activated killer cells and A549 lung carcinoma nodules maintained in three-dimensional culture.
Gharib M; Tamboise E; Tamboise A; Lièvre N; Vérola O; Beaupain R
Tumour Biol; 1997; 18(3):135-45. PubMed ID: 9143410
[TBL] [Abstract][Full Text] [Related]
39. Killing capacity of LAK cell transduced lymphocytes harvested by Haemonetics V50 lymphosurge technique.
Elias MK; de Ley L; Smit Sibinga CT; Das PC
Prog Clin Biol Res; 1990; 337():469-76. PubMed ID: 2353008
[No Abstract] [Full Text] [Related]
40. Secretion of mucoid material by lymphokine-activated killer cells: study by light and electron microscopy.
Ginsburg H; Coleman R; Davidson S; Yahav H; Khoury C
J Leukoc Biol; 1990 May; 47(5):393-408. PubMed ID: 2186162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
